Lead Sponsor

Sensimed AG

Age

50 - 99 years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of neovascular AMD or neovascular AMD with concomitant OAG
•* For neovascular AMD patients, IOP \<21 mmHg, normal RNFL (retinal nerve fiber layer) thickness and optic disc, in need of treatment with monthly anti-VEGF injections and with best-corrected Snellen visual acuity of 0.5 or better on the non-study eye
•* For OAG patients, open angle, with typical glaucomatous optic disc including diffuse or localized neuroretinal rim loss, excavation, and retinal nerve fiber layer defects, or repeated abnormal visual field defined as a pattern standard deviation outside of the 95% normal confidence limits or a Glaucoma Hemifield Test result outside normal limits
•* For OAG patients any IOP-lowering treatment should be unchanged since at least 4 weeks at study entry and remain stable throughout the study
•Aged ≥ 50 years
•Not more than 6 diopters spherical refraction equivalent in the study eye
•Having given written informed consent, prior to any investigational procedures

•Pigmentary glaucoma, exfoliative glaucoma, narrow or closed iridocorneal angle or any other concomitant ocular conditions (except cataract) in the study eye
•History of ocular incision or laser surgery on the study eye (except cataract extraction)
•Corneal or conjunctival abnormality in the study eye precluding contact lens adaptation
•Severe dry eye syndrome
•Subjects with irregular sleep schedule or with sleep apnea syndrome
•Subjects allergic to silicone
•Subjects not able to understand the character and individual consequences of the investigation
•Participation in other clinical research within the last 4 weeks
•Any other contra-indication listed in the TF user manual